成人急性乙型肝炎抗病毒治疗的探讨

张艳梅; 丁晓慧

成人急性乙型肝炎抗病毒治疗的探讨

吉林油田总医院感染内科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 4209
- HTML全文浏览量: 5
- PDF下载量: 798
- 被引次数: 0
出版历程
- 出版日期: 2011-12-20

Anti-viral therapy in adult patients with acute hepatitis B

摘要

摘要: 成人急性乙型肝炎大多呈自限性病程,但有5%～10%的慢性化几率,本文针对成人感染乙型肝炎病毒后是否需要抗病毒治疗、抗病毒治疗的时机、适应的患者群以及如何进行抗病毒治疗作一综述。
- 肝炎,乙型 /
- 肝炎病毒,乙型
Abstract: Adult patients with acute hepatitis B generally have self-limiting processes, but the ratio of chronicity is still 5%-10%.This article is focused on whether, when, and how to perform anti-viral therapy in acute hepatitis B adult patients.
- hepatitis B /
- hepatitis B virus

HTML全文

参考文献(36)

[1] 中华医学会.慢性乙型肝炎防治指南 (2010年版) [J].实用肝脏病杂志, 2011, 14 (2) :81-89.

[2]Guidotti LG, Lshikawa T, Hobbs MV, et al.Intracellular inac-tivation of the hepatitis B virus by cytotoxic T lymphocytes[J].Immunity, 1996, 4 (1) :25-36.

[3]Toyonaga T, Hino O, Sugai S, et al.Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver[J].Proc Natl Acad Sci U S A, 1994, 91 (2) :614-618.

[4]Guidotti LG, Rochford R, Chung J, et al.Viral clearance without destruction of infected cells during acute HBV infec-tion[J].Science, 1999, 284 (5415) :825-829.

[5]Webster GJM, Reigant S, Maini MK, et al.Incubation phase of acute hepatitis B in man:dynamic of cellular immune mechanisms[J].Hepatology, 2000, 32 (5) :1117-1124.

[6]Chisari FV, Ferrari C.Hepatitis B virus immunopathology[J].Springer Semin immunopathol, 1995, 17 (2) :261.

[7]Akbar SMF, Onlji M.Hepatitis B virus-infection mice:as in vestigative tool tostudy immunopathology during HBV infec-tion[J].Int J Exp Path, 1998, 79 (5) :279.

[8]Guidotti G, Lshikawa T, Hobbs MV, et al.Intracelluar inacti-vation of the hepatitis B virus by cytotoxic T lymphocytes[J].Immunity, 1996, 4 (1) :25-36.

[9]张萍, 颜学兵, 吴文漪, 等.慢性乙肝患者外周血单个核细胞Th1、Th2型细胞标记物及其细胞因子的表达[J].中华传染病杂志, 2003, 21 (1) :42-43.

[10]Penna A, Del Prete G, Cavalli A, et al.Predominant T-heiper1cytokine profile of hepatitis B[J].Hepatology, 1997, 25 (4) :1022-1027.

[11]郭芳, 魏来.急性乙型病毒性肝炎致病机理及转归[J].中华医学杂志, 2002, 82 (15) :1074-1077.

[12]陈从新.慢性乙型肝炎的临床分型及亚型建议[J].热带病与寄生虫学, 2004, 2 (4) :253-255.

[13]赵鸿, 田庚善.急性乙型肝炎和慢性乙型肝炎病毒感染急性发作鉴别诊断的临床研究[J].中华实验和临床病毒学杂志, 2004, 18 (4) :363-365.

[14]李振方, 赵琦, 徐昌清, 等.淋巴细胞计数联合HBV DNA定量检测在早期诊断重症肝炎及判断预后中的意义[J].胃肠病学和肝病病学杂志, 2003, 12 (1) :49-51.

[15]许军, 王齐欣, 蒋栋, 等.乙型肝炎病毒基因型与病情轻重的关系[J].中华肝脏病杂志, 2003, 11 (1) :11-13.

[16]关毅.干扰素在治疗急性乙型肝炎中的抗病毒作用[J].山西临床医药杂志, 2000, 9 (5) :337-338.

[17]梁扩寰, 李绍白.肝脏病学[M].第2版.北京:人民卫生出版社, 2006:656-657.

[18]叶春艳, 刘睿.基因重组干扰素治疗急性乙型肝炎疗效观察[J].吉林医学, 2005, 26 (4) :428-429.

[19]undu SS, Kundu AK, Pal NK.Interferon-alpha in the treat-ment of acute prolonged hepatitis B virus infection[J].J As-soc Physicians India, 2000, 48 (7) :669-670.

[20]Hoofnagle JH.Therapy of acute and chronic viral hepatitis[J].Adv Intern Med, 1994, 39:241-275.

[21]Halevy J, Achiron A, Spiegel D, et al.Recombinant alpha-interferon may be efficacious in acute hepatitis B[J].Am J Gastroenterol, 1990, 85 (2) :210-212.

[22]Kumar M, Statapathy S, Monga R, et al.A randomized con-trolled trial of lamivudine to treat acute hepatitis B[J].Hepa-tology, 2007, 45 (1) :97-101.

[23]Tillmann HL, Haden J, Leifeld L, et al.Safety and efficacy of lamivudine in patients with severe acute or fulminant hepa-titis B, a multicenter experience[J].J Viral Hepat, 2006, 13 (4) :256-263.

[24]Dienstag J, Easley C, Kinkpatricck P.Telbivudine[J].Nat Rer Drug Disoov, 2007, 6 (4) :267-268.

[25]Ruiz-Sanho A, Sheldon J, Soriano V.Telbivudine:a new option for the treatment of chronic hepatitis B[J].Expert Opin Bid Ther, 2007, 7 (5) :754-761.

[26]葛娅, 赵甫涛.抗乙型肝炎病毒新药—替比夫定的临床应用[J].中西医结合肝病杂志, 2008, 18 (1) :59-60.

[27]贾继东, 侯金林, 尹有宽, 等.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病学杂志, 2007, 15 (5) :342-345.

[28]马丽娜, 黄云丽, 张永宏, 等.急性乙型肝炎的临床转归及抗病毒效果观察[J].中国现代医学杂志, 2005, 15 (24) :3820-3822.

[29]羊正纲, 陈智.RNA干扰素抗HBV的研究进展[J].国外医学.流行病学传染病学分册, 2004, 31 (2) :91-93.

[30]Shomai A, Shaul Y.Inhibition of hepatitis B virus expression and replication by RNA interference[J].Hepatology, 2003, 37 (4) :764-770.

[31]唐霓, 黄爱龙, 张秉强, 等.应用RNA干扰技术抑制乙型肝炎病毒抗原表达的实验研究[J].中华医学杂志, 2003, 15:25-28.

[32]McCaffrey AP, Nakai H, Pandey K, et al.Inhibition of hepa-titis B virus in mice by RNA interference[J].Nat B iotechn-ol, 2003, 21 (6) :639-647.

[33]Siddhesh D, David C, Diang J.DNA-based the rapeutice and DNA delicery systems acom prehensive review[J].AAPSJ, 2005, 7 (1) :61-77.

[34]Ming-Kai X, Cheng-Gang Z.Gene expression and func-tion study of fusion immunotoxin anti-Her-2-scFv-SEC 2in Escherichia coli[J].Appl Microbiol Biotechnol, 2006, 70 (1) :78-84.

[35]Chougn S, Kin YJ, Kim S, et al.Chemical modifical of siRNA to improve serum stability without loss of efficacy[J].Bio-chen Biophys Res Cammun, 2006, 342 (3) :919-927.

[36]Wu RH, Cheng TL, Lo SR.A tightly regulated and reversibly inducble siRNA expression system for conditional RNA i-mediarted gene silcncing in mammaliam cells[J].Gene Med, 2007, 9 (7) :620.

施引文献

资源附件(0)

访问统计